-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 W0wDYps+X3O3oNpodu9H71lE0qJsH/TuUl69ZXrZGwLNUGLjm9uUipxB7nqvyIQz
 7Wa4NXLvtQJvOeDjvn0d9A==

<SEC-DOCUMENT>0001104659-10-033796.txt : 20101014
<SEC-HEADER>0001104659-10-033796.hdr.sgml : 20101014
<ACCEPTANCE-DATETIME>20100615061659
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-10-033796
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20100615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINOVAC BIOTECH LTD
		CENTRAL INDEX KEY:			0001084201
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			B9
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085
		BUSINESS PHONE:		86-10-82890088

	MAIL ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NET FORCE SYSTEMS INC
		DATE OF NAME CHANGE:	19991110
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>

<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="307" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41st Floor, One Exchange Square</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="307" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8 Connaught Place, Central</font></p>    <
/td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="307" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hong Kong</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="307" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: +852.2522.7886 Fax: +852.2522.7006</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p sty
le="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="307" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.lw.com</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="236" height="17" src="g120341bc01i001.jpg"></font></p>    </td>    <td width="307" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="272" height="19" src="g120341bc01i002.jpg"></font></p>    </td>   </tr>   <tr height="30" style="height:22.55pt;">    <td width="413" height="30" valign="top" style="height:22.55pt;padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;">
<font size="2" face="Times New Roman"><img width="125" height="19" src="g120341bc01i003.jpg"></font></p>    </td>    <td width="307" colspan="2" height="30" valign="bottom" style="height:22.55pt;padding:0in 0in 0in 0in;width:3.2in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FIRM / AFFILIATE OFFICES</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Abu Dhabi</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moscow</font></p>    </td> 
  </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Barcelona</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Munich</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" styl
e="font-size:10.0pt;">Beijing</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New Jersey</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brussels</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 
0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;15, 2010</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chicago</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orange County</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Doha</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0
in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paris</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIA EDGAR</font></u></b></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dubai</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Riyadh</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">
&nbsp;</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Frankfurt</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rome</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jim B. Rosenberg, Senior Assistant Chief</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hamburg</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .00
01pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">San Diego</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Don Abbott, Senior Staff Accountant</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hong Kong</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">San Francisco</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dana Hartz</font><font size="2" style="font-size
:10.0pt;">, Staff Accountant</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Houston</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shanghai</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Division of   Corporation Finance</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">London</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="ma
rgin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Silicon Valley</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities and Exchange Commission</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Los Angeles</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Singapore</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100 F Street, N.E.</font></p> 
   </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Madrid</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tokyo</font></p>    </td>   </tr>   <tr>    <td width="413" valign="top" style="padding:0in 0in 0in 0in;width:4.3in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, D.C. 20549-7010</font></p>    </td>    <td width="151" valign="top" style="padding:0in 0in 0in 0in;width:113.4pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Milan</font></p>    </td>    <td width="156" valign="top" style="padding:0in 0in 0in 0in;width:117.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times N
ew Roman" style="font-size:10.0pt;">Washington, D.C.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mail Stop 4720</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Sinovac Biotech Ltd. </font></b></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;20-F for the Fiscal Year Ended December&nbsp;31, 2009</font></u></b></p>
<p style="margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">File No.&nbsp;001-</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">32371</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Messrs.&nbsp;Rosenberg and Abbott and Miss&nbsp;Hartz:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter sets forth the response of Sinovac Biotech Ltd. (the &#147;<b>Company</b>&#148;) to the comments received by facsimile on June&nbsp;2, 2010 from the Staff of the Commission regarding the Company&#146;s annual report on Form&nbsp;20-F for the fiscal year ended December&nbsp;31, 2009 (the &#147;<b>2009 20-F</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For ease of reference, we have set forth the Staff&#146;s comments and the Company&#146;s response below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Information on the Company</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Research and Development, page&nbsp;32</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">We note the collaboration you have entered into with the National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention China CDC.&#160; Please file the co-development agreement you entered into in December&nbsp;2004 as an exhibit to your annual report or, if you believe it is not material and should not be filed, please provide us with the basis of this belief.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">   <tr>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Simon H. Berry</font></p>    </td>    <td width="128" valign="top" style="padding:0in 0in 0in 0in;width:95.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Raymond M. S. Kwok</font></p>    </td>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Chun Fai Woo</font></p>    </td>    <td width="204" valign="top" style="padding:0in 0in 0in 0in;width:153.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Registered Foreign Lawyers:</font></p>    </td>    <td width="140" valign="top" style="padding:0in 0in 0in 0in;wid
th:104.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">David Zhang <i>(New York)</i></font></p>    </td>   </tr>   <tr>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Joseph A. Bevash</font></p>    </td>    <td width="128" valign="top" style="padding:0in 0in 0in 0in;width:95.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Michael S. L. Liu</font></p>    </td>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Cheung Ying Yeung</font></p>    </td>    <td width="204" valign="top" style="padding:0in 0in 0in 0in;width:153.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Eugene Y. Lee <i>(New York)</i></font></p>    </td>    
<td width="140" valign="top" style="padding:0in 0in 0in 0in;width:104.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>   <tr>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Kenneth D. C. Chan</font></p>    </td>    <td width="128" valign="top" style="padding:0in 0in 0in 0in;width:95.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Jane M. S. Ng</font></p>    </td>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.0pt;">    <p style="margin:0in 0in .0001pt;"><i><font size="1" face="Arial" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>    <td width="204" valign="top" style="padding:0in 0in 0in 0in;width:153.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Dav
id J. Miles <i>(England and Wales)</i></font></p>    </td>    <td width="140" valign="top" style="padding:0in 0in 0in 0in;width:104.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>   <tr>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">Stanley Chow</font></p>    </td>    <td width="128" valign="top" style="padding:0in 0in 0in 0in;width:95.85pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:7.0pt;">John A. Otoshi</font></p>    </td>    <td width="124" valign="top" style="padding:0in 0in 0in 0in;width:93.0pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Arial" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="204" valign="top" style="padding:0in 0in 0in 0in;width:153.15pt;">    <p style="margin:0in 0in .0001pt;"><font size="1" face="Ari
al" style="font-size:7.0pt;">Allen C. Wang <i>(New York)</i></font></p>    </td>    <td width="140" valign="top" style="padding:0in 0in 0in 0in;width:104.85pt;">    <p style="margin:0in 0in .0001pt;"><i><font size="1" face="Arial" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\bvanga\10-12034-1\task4151792\12034-1-bc-01.htm',USER='bvanga',CD='Jun 15 03:45 2010' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The co-development agreements between the Company and the National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention in December 2004 and November 2006, disclosed on page 35 and page 33 of the 2009 20-F, respectively, are of a type in the ordinary course of the Company&#146;s business.&#160; As disclosed in the 2009 20-F, the Company regularly engages in co-development activities with other parties similar to those provided under these agreements.&#160; These co-development agreements are immaterial in amount or significance.&#160; The Company&#146;s business is not dependent upon these agreements.&#160; The Company will continue to monitor its dependence on the co-development agreements and will file them with the Commission in the event that the relevant circumstances change.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Suppliers, page 34</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Please file your agreement with Beijing Temple of Heaven as an exhibit to your annual report, if you believe this agreement is not material and should not be filed, please provide us with the basis of this belief.</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The agreement between Beijing Temple of Heaven and the Company is of a type in the ordinary course of the Company&#146;s business.&#160; This agreement sets forth the framework of the hepatitis B antigen supply relationship, under which Beijing Temple of Heaven and the Company entered into separate supply agreements to specify the pricing, quantity, delivery and payment terms.&#160; Each of the separate supply agreements is immaterial in amount or significance.&#160; The Company sources the hepatitis B antigens it uses for Bilive production entirely from Beijing Temple of Heaven.&#160; However, sales of Bilive accounted for only a small portion of the Company&#146;s total sales.&#160; The Company began marketing and selling Bilive in 2005, but sales of this product were limited before 2007.&#160; Revenue from sales of Bilive was $132,569, $1.7 million and $6.2 million in 2007, 2008 and 2009, respectively, 
accounting for 0.4%, 3.6% and 7.4% of the Company&#146;s total sales in 2007, 2008 and 2009, respectively.&#160; Purchases of the hepatitis B antigens from Beijing Temple of Heaven amounted to $102,006, $119,645 and $972,080 in 2007, 2008 and 2009, respectively.&#160; The Company&#146;s business is not dependent upon this agreement.&#160; The Company will continue to monitor its dependence on its supply agreements with Beijing Temple of Heaven and will file them with the Commission in the event that the relevant circumstances change.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Collaborations, page 35</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Please identify the counterparty of the technology transfer agreement you entered into in March 2009 and provide a range of the royalty payments based on net sales, e.g. &#147;single-digits,&#148; &#147;teens,&#146; &#147;twenties,&#148; etc.&#160; You should also file this agreement as an exhibit to your annual report.&#160; If you believe this agreement is not material and should not be filed, please provide us with the basis of this belief.</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The counterparty of the technology transfer agreement entered into by the Company in March 2009 is Tianjin CanSino Biotechnology Inc.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_130337_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105981\10-12034-1\task4151730\12034-1-bc-03.htm',USER='105981',CD='Jun 15 13:09 2010' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The percentage of royalty payments for the portion of annual net sales below RMB100 million will be in the teens and the percentages of royalty payments for the portion above RMB100 million will be of single digits.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company submits that this technology transfer agreement is immaterial in amount or significance.&#160; Under this technology transfer agreement, the Company agreed to make milestone payments of up to $3 million and has paid a total of $800,000 as of the date of this letter.&#160; Each of the future milestone payments is subject to certain conditions, including the PRC government approvals at different stages, which are uncertain.&#160; The Company also agreed to make royalty payments in eight years after the first sales of the vaccine developed under the technology transfer agreement in the Chinese market.&#160; The sales of the pneumococcal vaccine in the Chinese market are also subject to the PRC government approval.&#160; The Company will file this technology transfer agreement as an exhibit if the Company&#146;s business becomes substantially dependent upon this agreement.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5. Operating and Financial Review and Prospects<br> Critical Accounting Policies and Estimates<br> Revenue Recognition, page 43</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Please disclose the specific terms of the &#147;limited right of return&#148; that you provide to customers and the amount of your reserve for product returns for each period presented.</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will revise the disclosure in future filings to indicate that the Company provides its customers with a limited right of return.&#160; For Healive, Bilive and Anflu, the Company&#146;s customers are allowed to return the products within a specified period before expiration of their shelf lives, subject to the Company&#146;s approval.&#160; For Panflu and Panflu.1, the Company&#146;s customers do not have a right of return and the Company generally does not accept returned products.&#160; The Company accrues product return provision for Anflu in the periods when sales of Anflu are recorded and adjusts its estimation at the end of the year based on actual sales returns because the returned products are only accepted by the end of the flu season and the returned products are known prior to issuance of the financial statements.&#160; The Company&#146;s product return provisions for Healive and Bili
ve are estimated based on historical return and exchange levels, external data with respect to inventory levels in the wholesale distribution channel and remaining shelf lives of the Company&#146;s products at the date of sale.&#160; The Company&#146;s reserves for product returns are $649,379, $1,124,563 and $978,286 for 2007, 2008 and 2009, respectively.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Consolidated Financial Statements<br> Note 2, Significant Accounting Policies<br> (i) Income Taxes, page F-15</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Please revise to disclose your accounting policy for presenting VAT collected from customers on the income statement.&#160; If amounts are presented on a gross basis, disclose the percentage of the VAT applied to product sales and the amounts of VAT for each period presented.&#160; Refer to FASB ASC 605-45-50.</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will revise the disclosure in future filings to clarify that the Company&#146;s accounting policy for the VAT collected from customers relating to product sales and </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_130409_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105981\10-12034-1\task4151730\12034-1-bc-03.htm',USER='105981',CD='Jun 15 13:09 2010' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">remitted to governmental authorities are presented on a net basis and the VAT collected from customers is excluded from revenue.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k) Revenue Recognition, page F-16</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">You disclose that deferred revenue includes amounts received from the Chinese government for the stockpiling of vaccines.&#160; Please revise your disclosure to clarify your accounting policy for vaccine stockpiles and provide the disclosures contained in Section IV of Release 33-8642 issued in December 2005.</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company did not elect the alternative accounting method available for revenue recognition related to the sales of enumerated vaccines as set out in the Commission&#146;s Release 33-8642.&#160; The disclosures included in the 2009 20-F outline that revenue is not recognized until delivery unless shelf lives of the products expire prior to delivery.&#160; Therefore, the Company does not believe that any additional disclosures or any amendments to the current disclosure are necessary.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company does not believe that any of the forgoing amendments to the current disclosure would have a material impact on the Company&#146;s 2009 20-F and financial statements.&#160; Therefore, the Company does not propose to file an amendment to its 2009 20-F to include the amended disclosures above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company acknowledges that:</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Company is responsible for the adequacy and accuracy of the disclosure in the filing;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please do not hesitate to call me </font><font size="2" style="font-size:10.0pt;">at (852) 2912-2515 or by fax at (852) 2522-7006</font><font size="2" style="font-size:10.0pt;">, David Zhang at (852) 2912-2503 </font><font size="2" style="font-size:10.0pt;">or by fax at (852) 2522-7006, or Zheng Wang at (852) 2912-2585 or by fax at (852) 2522-7006 </font><font size="2" style="font-size:10.0pt;">with any questions or comments regarding this correspondence.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_130506_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105981\10-12034-1\task4151730\12034-1-bc-03.htm',USER='105981',CD='Jun 15 13:09 2010' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">   <tr>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>    </td>   </tr>   <tr>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>   <tr>    <td width="360" valign="top" s
tyle="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="360" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font><font size="2" style="font-size:10.0pt;">Eugene Y. Lee</font></p>    </td>   </tr>   <tr>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>    <td width="360" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>   <tr>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in
;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eugene Y. Lee</font></p>    </td>   </tr>   <tr>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="360" valign="top" style="padding:0in 0in 0in 0in;width:3.75in;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of LATHAM &amp; WATKINS</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 3.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Enclosures</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">   <tr>    <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">    <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc:</font></p>    </td>    <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weidong Yin, Chairman and Chief   Executive Officer</font></p>    </td>   </tr>   <tr>    <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">    <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.
0pt;">Jinling Qin, Acting Chief Financial   Officer</font></p>    </td>   </tr>   <tr>    <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">    <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">David T. Zhang, Esq., Latham &amp;   Watkins, Hong Kong</font></p>    </td>   </tr>   <tr>    <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">    <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Simon Anderson, Cha
irman of Audit   Committee</font></p>    </td>   </tr>   <tr>    <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">    <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>    <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Linda Zhu, Partner, Ernst &amp; Young   LLP</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_130652_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105981\10-12034-1\task4151730\12034-1-bc-03.htm',USER='105981',CD='Jun 15 13:09 2010' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g120341bc01i001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120341bc01i001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MP``+"``1`.P!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`-3X#.\GA?42[LQ^V]SG^!:]1KQKXGR:EXB\37EOI4SK
M'X9L?M4A0GF0LI(^H7!_X":]1\.:O'XB\-6.J)C%U`&<#LW1A^!!%>5^.?`6
MAZ%J?AR&Q%VJ:CJ"P7&ZY9B4)7.,].M>G^&_"FE^%89X=+68+.P9_-E+\@8X
MSTKA?ACXBTC2[778M4U>TM96U65E2XN%4E>.0">E6(-5LM5^.5K+IU_#=VXT
MIE+02AUW9;CCC/(KM/%>M+X>\+ZAJK$!K>$F,'NYX4?F17FOPQ;4?"_BR/1]
M5F=AKU@E[%O/23DD<]\;L_05ZQJ-R++3;J[/2"%Y#^`)_I7COP:U&\TWQ`^F
MW\C%-9M/M=ON.<LK,./J`WY56\>ZU=W/Q%758)&%AH-[;6I(/!<DNW_H)!^@
MKVG5=0CTK2;O49!N2UA:4KN`W8&<9/K67X:\2'6EE6<VFY2GER6TQ>.7<N[:
M"0#N4=1]*YC47;0OCAI]QO86^MV9A89X\Q>G_H*?G7+>-M9O5^)$GB&!W^P^
M'KJVM9`"<'=N+_\`LP_*NM\:2?VU\0/">A1.6A5VOY]IX*KRN?;Y6'XUM_$;
M7&T'P3?W$3$7,Z_9X`.I=^./<#)_"N5^%OVSPUX@U7P;J<I>41QWD!8]<J-X
M'YC\C6UX^\%:/JFGZGKURMQ]MM[%VC*3LJ@HI*\#CK67\,/!6CMH.C^)6%R=
M0*,Y8SMMSEE^[TZ4OCW4(=-^)?A.[N[@06T*3O*[-A0`.]/\-65YX\\1#QAJ
M\<D6EVQ*Z39/P&`/^M8=^?U]@,S_`!G9D\&VQ5BI_M"+D''9JZOQ,2/"6K$$
M@BQFY'^X:\E^%6OWGAK4[/2M5E)T_7HA-9RL>%ER5Q^)&#[[?6NN\+.Q^+_B
M]2Q*B.#`)X'RBLCQ[=6MW\2K+1_%-Y/:>'C:[T57*1RR<_?(]^/;CIFO0/#.
M@:/H&E?9]#'^AS2&=2)3("2`,@DGC@5Y7\'?%V@>'O#U];ZOJ<5I+)=;T5PQ
M)7:!G@>U>KP>)=(N]!GURTO$GL($=WE7('RC)ZUYEX,T[QW>Z=?:[IJZ*(M?
MF>:47XD+LN2,?+QMZX^M:_PBGNM(EUCP;J1076FS^:BJ204;KMSVS@_\"J?X
MI'&L^#?^PLG_`*$M>B5Y/\,O#6AZW;:[/J>E6MY*FJRHKS1AB%X./UJS:Z3I
MVC?'.UM=,LX;2$Z4SF.%=H+$MSC\*F^*KWFN:CHO@[2_*:YO)3<RK*3L"(#C
M=CG!^;_OFL+QS:>.-.73?%.KKH[+HMPK*;`2!]K,!@[N-O`'XUW7CK6(3\,=
M3U*WD!BNK(>4P/4284?^A5PWB.QE\->#_!/BFUCW3:4D2S`<;D==V#[9R/\`
M@5076A2CX#W>I7`S>7UT-2D8]3N<`?\`CIS^->E&W?Q1X)L'AF1)9HK>ZC:1
M=R,Z[7`8=U)&#5&S\,:NNOPZLYT^R2.;S9+*W9WCF<J5:7D#:^UCT'/>LSXP
M0O:Z1I7B*`?O='OXY<C^Z2,_J%K*T/P_)KGP?UNZFCS=ZU)-?C/7<K90?FOZ
MU#\(9Y_$GB&ZUZ[4DV&G06$9/<XY/_CN?^!5?\?MJ?B3QYI'AW1/LKS:8G]H
M2BZSY08$;0V.?3_OJLGQ,/%OASQ3HOC'Q%_9AC@F%K*^G[Q^[;.=V[V+8KTS
MQ8RMX+UEU8%3I\Q!!X(V&LWX7_\`).-&_P"N3?\`H;5SGQ#T^UU;XD^%-/OH
MA+;W$<Z2(>X(_G4G@_5[KP9XA;P)KTQ:!CNTF\DX$B$\(3Z^GOD>E6/C4<>#
M+;/_`$$(OY-76>)_^10U;_KPF_\`0#7G=KX3_P"$K^"6DK;#&HV4;S6CC@[@
M[97/OC\P*C^$&KW&N^,-=U"\7;<R6L"RY&,LH"DX]\9_&NW\5:OX,#_V1XHG
MLMQC$HBN5)PI)&0<<'@]#FO-O#-EXP:WOSX-N)(]"^WS?8_-/WDR,%=W.,8_
M'/?-0Q=OK7>:9_R3"^^DO\ZZ?PU_R+6G?]>Z_P`JQ;/_`)*???\`7H/Y)4GC
M+_D(:#_U_+_,5U-<KX$_X]=3_P"OY_Z4LO\`R4R#_KP/\S22?\E-B_Z\/ZFM
M'Q?_`,BIJ'_7,?S%8>J?\DLA_P"N,7_H0JYXI_Y)\?\`KE#_`#6I-4_Y)T?^
MO&/^0K1\-?\`(M:=_P!>Z_RK4K!\;?\`(HWWT3_T,5/X;_Y%6P_Z]A_*L/X:
M_P#(+O?^OC_V45:TO_DHFL?]>\?\EJ3Q_P#\BI-_UT3^=7[S_D3YO^O`_P#H
M%1^#_P#D5+#_`*YG_P!"-4->_P"1WT#_`+:?RJC\0/\`D(Z)_P!=C_Z$E:'C
M_P#Y`,7_`%])_6MK5_\`D!WO_7L__H)JCX-_Y%.P_P!P_P#H1K!\%?\`(U:[
F_OM_Z&:Y+XS_`/(QV'_7)?\`T(UZOH7_`"`-/_Z]H_\`T$5__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g120341bc01i002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120341bc01i002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MP``+"``3`1`!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/3_`!%K$VB:>+N&S>Z^;#*BL=H]3@&L+PQXYE\0W:1O
M9S09=U*+:R$8!(!+D`#IZ<=*=J_C&YTZ\MH85MYUEO/*)`8$)M;((QP00.>:
MOZ1XJ6X\-+JE_&1(KB-X[>-G)8D``#KG)Z46GC&WGNY()=.U*W43+$LDEHX7
M)QC<<?+R:S/$_C+4M'OKNTMHK%O(6-E)=V?#'G*X`X&3U[BF>$O&NHZQ%J,E
M]!#BT@,JB)2N<#)&<FJ,WQ0N8KQ(SI8\HHQ8A)2"1C!#;<$=?TK<UKQH=(AL
M66S$[7D)<,K_`"`\8`..>OI2>%/&,NOWC6-Q9B&:*-R[@X5F5RIP#SVS6!?_
M`!+U.U97^RV"1F27;FXRS!'9<$=B<9KHXO%5PFAV5_=6J&2ZN%C*6Q,JJI('
M)'?!Z5EZ+X[U#4?$4>GSVEK%`\KIYBS*6P,XXSGG`KI-7U2]MIV@TZ.UEFB@
M-Q,EQ(Z83)`P54YY!ZT:CK,EKX>BU*)(M\JQL!(QVC=CN.3C-<POQ&NG>Q"Z
M:"TB9NDVN2IR`=F`<\'OBNBUK6-4LY/LVGZ3Y\TH_<.]S$@<]2-K,&.!4F@:
M[)KD<SOITMF(FVD2RQLV[G((4G!'OZUS-S\0-1@661;&W98YO+VY?)&_;UQC
MWK:\6^);O0);6.TMK>8S132-Y\OEX$87@>I.[]*R?"GCG4->U'[+)#9>4@+2
M21S`MW(`7N>U-U7X@WEK'&UI8H2TTT;?:&\K`4C:1N(ZYYK1N/$^I'PM8ZE:
M6D+75QS(&8F*/')!*Y.3T'UJEHOC/6-3UF"VDM=/C@G8I_K7W*RC+`?+R>N,
MXZ&NNEU/3X)#'+?6T;KU5YE!'X9J*\U6*'2Y[VT>*Z\H<!)`03Z9&<=:YJ/Q
MCJOVLE[6Q^SNZPH/.8%9/,*,2=O3./P&>]:6K:]JEIJ(M;*SLI`&B0M/.Z$N
M^2``%/`VFH_#?BJXU82-J%M;6R+917@:&9I,(Y?ALJ,$;,_C47_">Z1_PD)M
M/[1M_L?V3S-^UL^9OQCZ8KHFU*Q2**62\AC29=T9DD"[AZC-$.HV5R_EV]Y!
M,^,[(Y58_D#7!Z[\1]2T]YXK/3H&9)9$WW$A79MQQ@9R>3Z5U_AC6)]>T*'4
M+BU6VDD+`HK[EX.,@\<53\<:1+J_AV2.UMC/=I)&T*AL8^==W?'W<]:PO#_A
M*ZM_$R2W^G[+1+=W1A(,+-YBL#P<Y^\?3K5K7_#6H:P?M<JR&4W)V1JX/DQ`
M8!4$@;CW-6M&\*"/PTVES-<VF;@2B191YAPP;<.H4YSTI;/PDXO;F2?4M4*+
M<I)&);G>LH4`\C'/(IWB'PYJ&HRWD\%TC+<0B$P%=N%&2.1R6R3[=*I:9X;O
M]#L]8M8(FG2\@40LT@)+$;2&]QDGC@CWK%;P/J\FH&,6T6!"6+RG<F3@%0P(
MYX)'&![UT&L^&[S6H;.)8([7RH5#O(5<J1V"@<GWZ5%X6\-:AH]Q;W-U&LQ\
MICN&U'1B.58#[Q]\US%S\.M8U"^DECM8(4";R)U7YI2S,0",YSN`R?2NJL/"
M]U)X/M=+F9[*>V)9DAVH))`<J=P[9_.LS2?!%W:Z[:W,T4@1)O-8[P4P/4>_
M&!77V-C)-?WNHWD`C>Y40(A.6$2YQGW)9CCWJA/HLL_A271KFW9Q:X2`Q$%I
M$4@IC/0XXY]*Y^Q\-ZPL"2S:4CSV\@90[A3)D^J]L`9KH-9TFXU2<FTM1:7Z
M[2-2<Y\L@?P+G)')&./?-2Z;;7%M9SVBZ7]DNDAV+/%("DN,X.X\YZG!'&>I
MKFYO"%V)9YOL4KRL_+QR+EW(X;)YP,@D\<C@5;\;>'-0UBVM+>WMS<2VUMY:
M2N%8%V9,DYZ<1GG_`&JH^$_!.I^'O$*W%Q!;M$T+!9844F-V]<@'CU[U)K/@
M2\ENBT4T]RK,9"[2`-N/WL#&!ST'K6@OAB^'AG3],@0HZS--(TD@^4DDKNP/
MFQD=/2F:!X4U+3+^"5Y$*QW,CRR,!EE.0-H[9^M=1-HVEW,S33Z99RR-RSO`
MK,?J2*J:OIBKHDMCIEC$GVAU5DB54`&1N)QCL/Y5R:>$[M-229;.Y\A(@BH1
M$<]N1WX[]:W;S0]5DU\:G9"Q")$@C2[WML8`@G"D#.#C)SWI/#'ANZT36+VY
MD@L(89X(D1;(.!N5G)R&)_O#O6B+2X_X3,WOE'[-_9PB\S(QO\PG'Y5?NM/L
M;XJ;RSM[@I]WSHE?'TR*C@TG3K1S):6%M;2E2!)%"JL,^X%>:ZW\/]2N-1=-
M+A=5:9F>294Q("<[BYR22>HQ7=^$-,N=(\/Q6-V[-)$2"&15`]<;>HSG!/-;
<=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g120341bc01i003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120341bc01i003.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MP``+"``3`'T!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`.\\4>(-3T;4H(K/$J302,L*Z7<7#LZ@D`/&V!DX&,<=
M>]4/#/C?4-8UMK&?1-6MHS,VZ6ZL&1(1Y:E4+#.TYW'YNQ'-6KKQ5J;7B&ST
M:[GL6OEBAN(3"!<($.X#S)`?O`X.`,#KS6GJNK7T'AR6^BL9K.Z#HBPW'ENP
MW2*N?D<J>#Q\WY5PX^(6OSSQ+:1,\3IO,DEO"N`<`$`3G</F'3GGC-;FO^+-
M5TZXM%ME1Q+9I,R+"6+.RR'@YXY0=CQD]JJ^$_&&JZUKEM:/J&GSQ/&TD\:J
MOF(%#+@;7^5B55BI!X8X(QBF^)_'&J:3%=M$8X5\QXT+^3^[*J,`,\B[GY)(
M`;&0.HYT+'QK=W?@V^UE[6"-X)/+CE:9%@?+!=VY'DP%SD_3BL8_$2_$5EMU
M&P&^5H9RNG3WH5$\X><)(BBN&,#$*%4X)/136SXIU[7M%%@]K>6#)<Q'<SZ?
M(PW@#)&)<@'<,`YQCJ:H^`O%'B'7YK2*^O+.2+[(LTK"Q=7?@#&[?M!R<Y"X
MX/`JEJ7CS4CJNJZ;87P22",A//LWC*$@MDEE7!"*<*?O$C!P":Z32]:U.Y\)
MSZM=:GIZL"6CD2PD81QAL?/$)-Q8@?=!!!.,'%4'\9SQ3PV5QK&EVYN!*6O;
MNUEL1!L\O*>5*Q+.?,!&2!@=#7:6LL<]K%-#.MQ'(@9)D((D!'#`C@YZ\<5C
M^(_#,?B"WE$EU<AQ`Z01+,8HU=E(R2@#$'(R"2.!QUSB>'?AZ/#OB./4;<V;
M1%7WE(O+="6E(50`<C$BC.1_JEX_NS:UX9NM5U%;I_"GAN9UN!(\T]P3).H!
M`#?Z.>V.YQCO5VZTS46\*2Z?;:386$B2QFWM[&?,8`D5R>8T"\[CT/XYQ7*?
M\(%K5L1)9V\:&-<(!<1@\C#?=B4#(``P!C^717_A>XU.>/SXMT,=A`AA:15C
MFD1G.UR`6P,@_+C/3/6JOASPKJ%EJAN[P3S0QW&R**]O))"J"-1YJC>Z@EPY
M`/.&ZC&*34_!UY/IE[#9!($224V]JH(WAL8Y#@#/N#5^[\-WT'A6\TZ"47LT
MTT<B+YCP]'0GYR[,O"]1R.PS7/R>"?$5U=B29DB$LPCS)=/>&",1W:[MSE6<
M?OT`YSUR`!6_XK\.7%];0S6JBZ>VCVB!XU8MT'R;F4`^N3V%9_@_P+>Z,^FW
M=W<0Q2VUJ(WB@3!+$+D,V?F`Q^-0WW@R]N;S4@;1IWNHX5CO7N?*(E!F+R_(
MVX#$H4+[8/'-:5KX6FM?#MW816VV;4)PLC/<L[Q0Y`YD/S'"AB!GJW&.RW?A
M4QW5Q)86\NU;<QHTUTTKS.[QLY+.Q.`(D')]?QZZBBBBBBBBBBBBBBBBO__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
